Loading...

NKTR NEKTAR THERAPEUTICS Expansion Plans 8-K Filing

NKTR

NKTR

NEKTAR THERAPEUTICS

(NKTR)

2025 8-K

Management Change

New Clinical Data

Financial Results

New Clinical Data

Financial Statements

Equity Offerings

Compliance Issues

Product Expansion

Reverse Stock Split

Reverse Stock Split

Financial Statements

Financial Results

Clinical Trial Agreement

Management Change

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results

Compliance with Minimum Bid...

Amendment to Purchase Agree...

Securities Purchase Agreement

Stock Repurchase

Earnings Reports

Financial Results Announcement

Financial Results Announcement

Disclosure and Other Events

Management Change

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Agreement

Restructuring Plan and CFO ...

External Links:

On June 24, 2025, Nektar Therapeutics reported positive topline results from its Phase 2b REZOLVE-AD clinical trial for atopic dermatitis, showing significant improvements in patient scores compared to placebo. The trial involved 393 participants and demonstrated a mean Eczema Area and Severity Score improvement of 61% with the highest dose (p<0.001).

AI Assistant

NEKTAR THERAPEUTICS

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.